1. Post-Test

 

* 1. After having attended this webinar, now how comfortable are you in monitoring and managing the immune-related AEs associated with I-O treatment?

* 2. Which of the following AEs are most commonly associated with immune checkpoint inhibitors?

* 3. When do immune-related side effects with single agent checkpoint inhibition typically start to appear?

* 4. Which of the following symptoms would you monitor and follow up with closely for suspicion of an immune-related AE?

* 5. If your patient delayed their I-O dose for management of grade 2 colitis with oral corticosteroids, which of the following best describes when you would be able to resume their I-O therapy?

Page1 / 2
 
50% of survey complete.

T